NeuroHealing Receives Notice of Allowance from the U.S. Patent and Trademark Office for a New Treatment for Premature Ejaculation

Newton, Massachusetts – October 13, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for a patent entitled “Modafinil-based Treatment for Premature Ejaculation.” The patent (US…

Details
NeuroHealing

NeuroHealing Pharmaceuticals Announces Publication Supporting the Use of NH001 to Treat Patients in a Coma and Issuance of NH001 Patent

Article published in April 2010 issue of Brain Injury Newton, Massachusetts – April 14, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the publication of a scientific article in the journal Brain Injury, supporting the use and further development of NH001…

Details
NeuroHealing

NeuroHealing Announces Formation of Medical Advisory Board for NH02D Program

Board members include medical experts and leading clinical investigators in the field of men’s sexual health Newton, Massachusetts – August 21, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the formation of a Medical Advisory Board (MAB) to assist the company…

Details
NeuroHealing

Interim Results of Phase II Trial for the Treatment of Sialorrhea to be Presented at Movement Disorder Society International Congress June 11th

NH004 produced a dose-dependent decrease in drooling in Parkinson’s patients Newton, Massachusetts – June 9, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the presentation of pre-planned interim clinical results of a phase II trial with NH004 for the treatment of…

Details
NeuroHealing

NeuroHealing to Present Data on NH02D Premature Ejaculation Drug at AUA Meeting

Positive Effect of Acute NH02D Administration for Treatment of Premature Ejaculation Newton, Massachusetts – April 13, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the presentation of positive preclinical results of its premature ejaculation drug NH02D at the American Urological Association…

Details
NeuroHealing